Skip to main content

Table 2 Measurements of cardiac function by echocardiography

From: I(f) current channel inhibitor (ivabradine) deserves cardioprotective effect via down-regulating the expression of matrix metalloproteinase (MMP)-2 and attenuating apoptosis in diabetic mice

  Ivabradine (n = 7) Control(n = 6) P value
IVSTd (mm)    
  Baseline 0.95 ± 0.12 0.89 ± 0.18 0.539
  At 3 months 1.09 ± 0.12 0.94 ± 0.15 0.089
IVSTs (mm)    
  Baseline 1.37 ± 0.17 1.29 ± 0.21 0.468
  At 3-month 1.59 ± 0.03 1.24 ± 0.21 0.022
LVDd (mm)    
  Baseline 3.30 ± 0.31 3.33 ± 0.27 0.932
  At 3-month 2.99 ± 0.14 3.24 ± 0.25 0.497
LVDs (mm)    
  Baseline 2.09 ± 0.17 2.26 ± 0.50 0.436
  At 3-month 1.65 ± 0.08 2.22 ± 0.53 0.017
LVPWd (mm)    
  Baseline 0.92 ± 0.18 0.84 ± 0.12 0.353
  At 3-month 1.09 ± 0.09 0.94 ± 0.16 0.067
LVPWs (mm)    
  Baseline 1.21 ± 0.09 1.18 ± 0.11 0.577
  At 3-month 1.42 ± 0.09 1.26 ± 0.14 0.032
EF (%)    
  Baseline 67.1 ± 6.96 61.6 ± 7.6 0.202
  At 3-month 75.7 ± 3.43 54.1 ± 8.3 0.018
FS (%)    
  Baseline 36.42 ± 5.56 31.66 ± 4.96 0.135
  At 3-month 49.33 ± 3.01 27.34 ± 4.87 <0.001
LVM (g)    
  Baseline 107.55 ± 10.75 99.81 ± 15.88 0.596
  At 3-month 85.85 ± 13.04 98.39 ± 27.92 0.309
LVM-corrected(mm)    
  Baseline 86.04 ± 8.59 79.99 ± 28.77 0.605
  At 3-month 66.65 ± 10.51 78.60 ± 22.30 0.230
LVDd (ml)    
  Baseline 44.84 ± 10.25 51.99 ± 25.65 0.509
  At 3-month 48.07 ± 6.69 49.32 ± 28.40 0.911
LVSd (ml)    
  Baseline 14.42 ± 2.67 19.79 ± 10.24 0.206
  At 3-month 11.97 ± 2.02 19.82 ± 11.06 0.091
  1. IVST, inter-ventricular septal thickness; d, end-diastolic; s, end-systolic; LVD, left ventricular dimension; LVPW, left ventricular posterior wall; EF, eject fraction; FS, fraction of shortness; LVM, left ventricular mass.